Table 1.
Clinicopathological characteristics of IPMs and NPMs
| IPM | Relative incidence (%) | NPM | Relative incidence (%) | |
|---|---|---|---|---|
| Median Breslow thickness | 2.0 mm | 0.35 mm | ||
| Median clark level | IV | I/II | ||
| Subtype | ||||
| SS | 6 | 46 | 4 | 29 |
| Nodular | 4 | 31 | 1 | 7 |
| LMM | – | – | 1 | 7 |
| MBN | 1 | 8 | – | – |
| Desmoplastic | 2 | 15 | – | – |
| MIS/LM | – | – | 6 | 43 |
| Mucosal | – | – | 2 | 14 |
| Location | ||||
| Trunk | 7 | 54 | 7 | 50 |
| Head and neck | 3 | 23 | 2 | 14 |
| Upper limb | 1 | 8 | 4 | 29 |
| Lower limb | 2 | 15 | 1 | 7 |
| Ulceration | ||||
| Yes | 5 | 38 | – | 0 |
| No | 8 | 62 | 14 | 100 |
| BRAF status | ||||
| WT | 5 | 38 | 2 | 14 |
| V600E/K | 2 | 15 | 2 | 14 |
| Unknown | 6 | 46 | 10 | 72 |
| TIL grade | ||||
| 0 | – | – | 5 | 36 |
| 1 | – | – | 0 | 0 |
| 2 | – | – | 1 | 7 |
| 3 | – | – | 3 | 21 |
| Nodal status | ||||
| Clinically positive | 1 | 8 | – | 0 |
| Sentinel node positive | 5 | 38 | – | 0 |
| Node negative | 7 | 54 | 14 | 100 |
| ITMs | 2 | 15 | 2 | 14 |
| Stage prior to commencing immunotherapy | ||||
| IIIA | 1 | 8 | – | – |
| IIIB | – | – | – | |
| IIIC | 1 | 8 | – | – |
| IIID | – | – | – | |
| IV | 11 | 84 | – | – |
ITMs, in‐transit metastases; LM, lentigo maligna; LMM, lentigo maligna melanoma; MBN, malignant blue naevus; MIS, melanoma in situ; SS, superficial spreading; WT, wild type.